EMA Authorised: Ultomiris (ravulizumab) — Alexion Europe SAS

View source ↗

Summary

EMA authorises Ultomiris (ravulizumab) for paroxysmal hemoglobinuria (PNH), with Alexion Europe SAS as the marketing authorisation holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• ULTOMIRIS (ravulizumab)

Snippet

Status: Authorised. Therapeutic area: Hemoglobinuria, Paroxysmal. MAH: Alexion Europe SAS. Decision date: 25/06/2026